(Q38151957)

29 August 2017

title

Role of platelets in inflammation and cancer: novel therapeutic strategies (English)

1 reference

29 August 2017

author

Paloma Guillem-Llobat

object named as

Paloma Guillem-Llobat

3

0 references

Melania Dovizio

object named as

Melania Dovizio

1

0 references

author name string

Sara Alberti

2

1 reference

29 August 2017

Paola Patrignani

4

1 reference

29 August 2017

publication date

8 November 2013

1 reference

Basic and Clinical Pharmacology and Toxicology

29 August 2017

published in

1 reference

29 August 2017

volume

114

1 reference

29 August 2017

issue

1

1 reference

29 August 2017

page(s)

118-127

1 reference

Platelets in inflammation and atherogenesis.

29 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12156

Platelet activation and atherothrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12156

Cyclooxygenase isozymes: the biology of prostaglandin synthesis and inhibition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12156

Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12156

Antiplatelet drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12156

Historical lessons in translational medicine: cyclooxygenase inhibition and P2Y12 antagonism

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12156

Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12156

Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12156

Cyclooxygenase-selective inhibition of prostanoid formation: transducing biochemical selectivity into clinical read-outs

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12156

Mechanistic and pharmacological issues of aspirin as an anticancer agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12156

Prostaglandins and inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12156

Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12156

Role of dose potency in the prediction of risk of myocardial infarction associated with nonsteroidal anti-inflammatory drugs in the general population

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12156

Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12156

Platelet genomics and proteomics in human health and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12156

De novo synthesis of cyclooxygenase-1 counteracts the suppression of platelet thromboxane biosynthesis by aspirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12156

Platelet microRNA-mRNA coexpression profiles correlate with platelet reactivity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12156

MicroRNA Involved in Inflammation: Control of Eicosanoid Pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12156

MicroRNAs in platelet production and activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12156

The mRNA binding proteins HuR and tristetraprolin regulate cyclooxygenase 2 expression during colon carcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12156

Activated platelets can deliver mRNA regulatory Ago2•microRNA complexes to endothelial cells via microparticles

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12156

Insights into the platelet releasate

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12156

Angiogenesis is regulated by a novel mechanism: pro- and antiangiogenic proteins are organized into separate platelet alpha granules and differentially released

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12156

Platelet-associated PF-4 as a biomarker of early tumor growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12156

Platelets at work in primary hemostasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12156

Platelet biology and receptor pathways.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12156

Thromboxane A2: physiology/pathophysiology, cellular signal transduction and pharmacology

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12156

Platelet--cancer interactions: mechanisms and pharmacology of tumour cell-induced platelet aggregation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12156

Effects of celecoxib on prostanoid biosynthesis and circulating angiogenesis proteins in familial adenomatous polyposis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12156

Pharmacological inhibition of platelet-tumor cell cross-talk prevents platelet-induced overexpression of cyclooxygenase-2 in HT29 human colon carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12156

Inhibition of tumor cell metastasis by modulation of the vascular prostacyclin/thromboxane A2 system

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12156

Microvesicles derived from activated platelets induce metastasis and angiogenesis in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12156

Microparticles: protagonists of a novel communication network for intercellular information exchange

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12156

Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12156

Low-dose aspirin for the prevention of atherothrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12156

Novel targets for platelet inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12156

Novel antiplatelet agents in development: prasugrel, ticagrelor, and cangrelor and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12156

Novel antiplatelet drug revacept (Dimeric Glycoprotein VI-Fc) specifically and efficiently inhibited collagen-induced platelet aggregation without affecting general hemostasis in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12156

Platelet GPVI: a target for antithrombotic therapy?!

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12156

Regulation of platelet membrane levels of glycoprotein VI by a platelet-derived metalloproteinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12156

Focusing on plasma glycoprotein VI.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12156

Paired analysis of urinary thromboxane B2 metabolites in humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12156

Isoprostanes: potential markers of oxidant stress in atherothrombotic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12156

Measurement of 8-iso-prostaglandin F2alpha in biological fluids as a measure of lipid peroxidation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12156

Local amplification of platelet function by 8-Epi prostaglandin F2alpha is not mediated by thromboxane receptor isoforms

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12156

Platelet activation in patients with colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12156

Blood flow and vascular gene expression: fluid shear stress as a modulator of endothelial phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12156

Induction of prostacyclin by steady laminar shear stress suppresses tumor necrosis factor-alpha biosynthesis via heme oxygenase-1 in human endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12156

Increased Prostacyclin Biosynthesis in Patients with Severe Atherosclerosis and Platelet Activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12156

Clinical relevance of microparticles from platelets and megakaryocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12156

Transcellular activation of platelets and endothelial cells by bioactive lipids in platelet microparticles

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12156

Glycoprotein VI-mediated platelet fibrinogen receptor activation occurs through calcium-sensitive and PKC-sensitive pathways without a requirement for secreted ADP

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12156

Cyclooxygenase-2-derived prostaglandin E₂ promotes injury-induced vascular neointimal hyperplasia through the E-prostanoid 3 receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12156

Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12156

Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12156

Effects of regular aspirin on long-term cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12156

Contribution of platelets to tumour metastasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12156

Is cyclooxygenase-2 the alpha and the omega in cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12156

Regulation of tumor progression by extracellular galectin-3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12156

Inflammation-mediated genetic and epigenetic alterations drive cancer development in the neighboring epithelium upon stromal abrogation of TGF-β signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12156

Prostaglandin E2 promotes colon cancer cell growth through a Gs-axin-beta-catenin signaling axis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12156

EP2 prostanoid receptor promotes squamous cell carcinoma growth through epidermal growth factor receptor transactivation and iNOS and ERK1/2 pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12156

Coxibs: pharmacology, toxicity and efficacy in cancer clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12156

A randomized trial of aspirin to prevent colorectal adenomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12156

A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12156

Mode of action of aspirin as a chemopreventive agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12156

Deciphering the human platelet sheddome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12156

Oral antiplatelet therapy for atherothrombotic disease: current evidence and new directions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12156

Clinical pharmacology of platelet, monocyte, and vascular cyclooxygenase inhibition by naproxen and low-dose aspirin in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12156

Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12156

Suppression of thromboxane A2 but not of systemic prostacyclin by controlled-release aspirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12156

Biopharmaceutical characterisation of a low-dose (75 mg) controlled-release aspirin formulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12156

Platelet granules: surprise packages

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12156

21 January 2018

Identifiers

DOI

10.1111/BCPT.12156

1 reference

29 August 2017

1 reference